Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE: TMO) has announced that their chairman, president and CEO Marc N. Casper will deliver a presentation at the Wolfe Healthcare Conference. The presentation is scheduled for Tuesday, November 19, 2024, at 8:00 a.m. EDT. Interested parties can watch the live webcast through the Investors section of Thermo Fisher's website.

Thermo Fisher Scientific (NYSE: TMO) has announced its Board of Directors has approved a quarterly cash dividend of $0.39 per common share. The dividend will be paid on January 15, 2025, to shareholders who are on record as of December 13, 2024.

Thermo Fisher Scientific (NYSE: TMO) reported Q3 2024 financial results with revenue of $10.60 billion, flat compared to $10.57 billion in Q3 2023. GAAP EPS was $4.25, down from $4.42, while adjusted EPS reached $5.28, compared to $5.69 in the prior year. The company's operating margin decreased to 17.3% from 17.6% year-over-year.

The quarter featured launches of innovative products, including the Iliad scanning transmission electron microscope and MagMAX Sequential DNA/RNA kit. Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07 and maintained revenue guidance of $42.4-$43.3 billion.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has announced its plans to release third quarter 2024 financial results before the market opens on Wednesday, October 23, 2024. The company will hold a conference call at 8:30 a.m. EDT on the same day to discuss its financial performance and future expectations.

Investors can participate in the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S., using the access code 296868. The call will also be available for live listening on the "Investors" section of Thermo Fisher's website. A replay of the call will be accessible under "News, Events & Presentations" until Wednesday, November 6, 2024.

Thermo Fisher Scientific (NYSE: TMO) hosted its 2024 Investor Day, showcasing its industry-leading businesses and proven growth strategy. The company highlighted its position in a $235 billion market with long-term growth of 4% to 6%. Thermo Fisher emphasized its high-impact innovation, customer partnerships, and unparalleled commercial engine.

The company's Practical Process Improvement (PPI) Business System was presented as a core element driving competitive advantage and financial performance. Thermo Fisher outlined its disciplined capital deployment approach, focusing on strategic M&A and returning capital to shareholders. The company projects long-term organic revenue growth of 7% to 9% and mid-teens adjusted EPS growth.

Thermo Fisher Scientific, the global leader in serving science, has announced that its chairman, president, and CEO, Marc N. Casper, will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference. The presentation is scheduled for Thursday, September 5, 2024, at 8:30 a.m. EDT.

Investors and interested parties can access a live webcast of the presentation through the Investors section of Thermo Fisher's official website, www.thermofisher.com. This event provides an opportunity for stakeholders to gain insights into the company's strategies, performance, and future outlook directly from its top leadership.

Thermo Fisher Scientific (NYSE: TMO) reported its Q2 2024 financial results, with revenue slightly declining 1% to $10.54 billion. Despite this, the company saw improvements in profitability, with GAAP diluted EPS increasing 15% to $4.04 and adjusted EPS rising 4% to $5.37. The company's GAAP operating margin expanded to 17.3% from 14.8% in Q2 2023.

Thermo Fisher launched several innovative products during the quarter, including new mass spectrometers and sustainable bioprocessing solutions. The company also expanded its clinical trial supply services and completed the acquisition of Olink, enhancing its protein research capabilities. Based on strong performance, Thermo Fisher raised its full-year 2024 guidance, projecting revenue between $42.4 to $43.3 billion and adjusted EPS of $21.29 to $22.07.

CytoReason, a leader in computational disease modeling, has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. The investment will be used to expand disease models, grow proprietary data, and establish a US hub in Cambridge, Massachusetts. CytoReason's technology provides molecular-level insights and AI tools to help pharma companies make data-driven R&D decisions, improving the probability of phase 2 success.

The company has partnerships with six of the world's top ten pharma companies and has published numerous scientific articles in prestigious journals. This funding round highlights the growing importance of AI and data modeling in pharmaceutical R&D, with investors recognizing CytoReason's potential to revolutionize drug development processes.

Thermo Fisher Scientific (NYSE: TMO) has announced a quarterly cash dividend of $0.39 per common share. This dividend is payable on October 15, 2024, to shareholders who are on record as of September 13, 2024. The announcement was made by the company's Board of Directors as part of their regular dividend policy.

This move reflects Thermo Fisher's ongoing commitment to providing consistent returns to its shareholders, reinforcing investor confidence in the company's financial stability and future growth prospects.